NCT06199336View on ClinicalTrials.gov

A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

January 19, 2024

Primary Completion Date

September 9, 2024

Study Completion Date

September 9, 2024

Conditions
Moderate to Severe Glabellar Lines
Interventions
BIOLOGICAL

JHM03

Single treatment, intramuscularly injected into five sites. The total injection volume is 0.5 ml,0.1 ml per site.

BIOLOGICAL

BOTOX®

Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.

BIOLOGICAL

Placebo

Single treatment,intramuscularly injected into five sites.The total injection volume is 0.5 ml,0.1 ml per site.

Trial Locations (1)

Unknown

Guangdong Second Provincial General Hospital, Guangzhou

All Listed Sponsors
lead

JHM BioPharma (Tonghua) Co. , Ltd.

NETWORK

NCT06199336 - A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines | Biotech Hunter | Biotech Hunter